Methods of treatment
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsChristopher John FRANCIS, Hua-Xin GAO, Yufeng LI, Niranjan YANAMANDRA
Life of this patent
Estimating the term…
Abstract
Disclosed herein are combinations of an OX40 modulator and a TLR4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.
Claims15
A method of treating cancer in a human patient in need thereof, the method comprising administering to the patient a combination of a humanized OX40 monoclonal antibody comprising:
- (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:1;
- (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2;
- (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3;
- (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:7;
- (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:8;
- and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:9;
- and a TLR4 agonist, which is CRX-601, having the formula shown below:
A method of treating cancer in a human patient in need thereof, the method comprising administering to the patient a humanized OX40 monoclonal antibody comprising a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO:5;
- and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:11;
- and a TLR4 agonist, which is CRX-601, having the formula shown below:
A method of treating cancer in a human patient in need thereof, the method comprising administering to the patient:
- a first pharmaceutical composition comprising a therapeutically effective amount of a humanized OX40 monoclonal antibody comprising:
- (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:1;
- (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2;
- (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3;
- (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:7;
- (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:8;
- and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:9;
- and a second pharmaceutical composition comprising a therapeutically effective amount of a TLR4 agonist, which is CRX-601, having the formula shown below:
A method of treating metastatic cancer, the method comprising:
- (i) systemically administering a therapeutically effective amount of an OX40 monoclonal antibody, the OX40 monoclonal antibody comprising:
- (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:1;
- (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2;
- (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3;
- (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:7;
- (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:8;
- and,
- (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:9;
- and,
- (ii) intratumorally administering a therapeutically effective amount of a pharmaceutical composition comprising CRX-601.
Dependencies are inferred from the claim text.